DEF 14A: Enfusion, Inc. Announces Details for 2024 Annual Stockholders Meeting

Enfusion, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on the election of directors and ratification of the company's independent auditor.

Summary

• Enfusion, Inc. is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, virtually.
• Stockholders will vote on the election of Oleg Movchan and Jan R. Hauser as Class III Directors to serve until the 2027 annual meeting.
• They will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR the director nominees and FOR the ratification of Ernst & Young LLP's appointment.
• The record date for determining stockholders eligible to vote is April 24, 2024.
• Stockholders can vote online, by telephone, or by mail before the meeting, or online during the meeting.
• The proxy statement and annual report are available online, and stockholders may request printed copies.
• The company has adopted a compensation recovery policy to recoup erroneously awarded compensation from executive officers in the event of an accounting restatement.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication with a neutral tone. It provides necessary information for stockholders to make informed decisions, and the Board expresses confidence in the company's direction.

Positives

• The company is embracing technology by holding a virtual annual meeting, which provides easy access and cost savings.
• The Board has a compensation recovery policy in place, aligning with best practices in corporate governance.
• The Board consists of a majority of independent directors, ensuring independent oversight of management.
• Stockholders have multiple avenues to communicate with the Board and individual directors.

Risks

• The Tax Receivable Agreement could have a substantial negative impact on the company's liquidity if payments exceed actual cash tax benefits or if distributions from Enfusion Ltd. LLC are insufficient.
• Changes in tax laws or rates could result in payments under the Tax Receivable Agreement exceeding actual tax benefits.
• The company may need to incur additional indebtedness to finance payments under the Tax Receivable Agreement.
• The limitation of liability and indemnification provisions for directors and executive officers may discourage lawsuits against them.

Future Outlook

The company does not provide specific financial guidance in this document, but it outlines the process for stockholders to propose actions for consideration at next year's annual meeting.

Management Comments

• Oleg Movchan, Chief Executive Officer, expressed gratitude for stockholders' ongoing support and continued interest in Enfusion.

Industry Context

This document is a standard proxy statement, which is a common practice for publicly traded companies to inform stockholders and solicit votes on important matters.

Comparison to Industry Standards

• The corporate governance practices outlined in the document, such as having a majority of independent directors and establishing key committees (Audit, Compensation, Nominating and Corporate Governance), align with the listing standards of the New York Stock Exchange (NYSE) and SEC regulations.
• The compensation policies for executive officers and non-employee directors are typical for publicly traded companies of similar size and industry, as informed by independent third-party benchmark analytics.
• The Tax Receivable Agreement is a complex financial arrangement that is not uncommon in companies that have undergone a reorganization prior to an IPO, as it allows pre-IPO owners to benefit from tax attributes generated from the reorganization.
• The indemnification agreements for directors and executive officers are standard practice to attract and retain qualified individuals.

Corporate Governance

Related Party Transactions

• The company distributed approximately $1.5 million to FTV Fund IV, representing a tax refund owed to FTV Enfusion Holdings, Inc.
• The company had a private placement in which it sold 1.2 million shares of Class A common stock to FTV Holdings and an affiliate of FTV Holdings for $9.7 million.
• Ali Hammoud, son of Tarek Hammoud (a former director and control person of LRA Ventures, LLC), is employed in the company's revenue department and earned approximately $239 thousand in 2023.

Stakeholder Impact

• Stockholders are provided with information to make informed decisions regarding the election of directors and ratification of the auditor.
• The compensation recovery policy aims to protect shareholder value by holding executives accountable for financial reporting accuracy.
• The Tax Receivable Agreement could impact the company's financial performance and liquidity, potentially affecting shareholder returns.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals before the deadlines.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Ernst & Young, Stockholders, Corporate Governance, Executive Compensation, Audit Committee, Voting, Enfusion